Supplemental Table 2: Comparison of direct CV-related costs between SPC and MPC cohorts (absolute numbers; based on matched cohorts).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **BIS/AMLO** | **VAL/AMLO** | **CAR/AMLO** | **VAL/AMLO/HCTZ** | **RAMI/AMLO** | **EZE/ATOR** | **ASA/ATOR/RAMI** |
| **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** | **SPC** | **MPC** |
| Cost of CV-related hospitalizations ppy | 233.66 € | **311.10 €** | 2,729.07 € | **3,640.84 €** | 117.35 € | **264.68 €** | 343.98 € | **924.47 €** | 199.12 € | **341.47 €** | 518.72 € | **1,309.47 €** | 374.60 € | **1,070.48 €** |
| Cost of outpatient visits ppy | 460.90 € | **467.14 €** | 547.03 € | **571.83 €** | 481.62 € | **514.81 €** | 551.14 € | **596.94 €** | 470.58 € | **496.46 €** | 429.00 € | **473.85 €** | 342.91 € | **367.46 €** |
| Cost of CV-related prescriptions ppy | 318.14 € | **345.32 €** | **789.54 €** | 404.09 € | 376.83 € | **396.79 €** | **770.11 €** | 548.57 € | **355.05 €** | 269.44 € | 1,292.30 € | **1,330.09 €** | **450.33 €** | 436.67 € |
| Sum of direct CV-related healthcare costs ppy | 1,012.70 € | **1,123.56 €** | 4,065.64 € | **4,616.76 €** | 975.80 € | **1,176.28 €** | 1,665.23 € | **2,069.98 €** | 1,024.75 € | **1,107.37 €** | 2,240.02 € | **3,113.41 €** | 1,167.84 € | **1,874.61 €** |

BIS/AMLO= bisoprolol/amlodipine; VAL/AMLO= valsartan/amlodipine; CAR/AMLO = candesartan/amlodipine; VAL/AMLO/HCTZ= valsartan/amlodipine/hydrochlorothiazide; RAMI/AMLO = ramipril/amlodipine; EZE/ATOR = ezetimibe/atorvastatin; ASA/ATOR/RAMI = acetylsalicylic acid /atorvastatin/ramipril; ppy= per patient-year. Bold= higher value.

*Legend: Supplemental Table 2 outlines the absolute results of the assessment of direct CV-related cost. All numbers were reported in € per observed patient-year (ppy).*